Browse by author
Lookup NU author(s): Dr Natalie Bell, Dr Helen Blair, Dr Simon BomkenORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
Burkitt lymphoma (BL) accounts for almost two-thirds of all B cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.
Author(s): Forde S, Matthews JD, Jahangiri L, Lee LC, Prokoph N, Malcolm TIM, Giger OT, Bell N, Blair H, O'Marcaigh A, Smith O, Kenner L, Bomken S, Burke GAA, Turner SD
Publication type: Article
Publication status: Published
Journal: British Journal of Haematology
Year: 2021
Volume: 192
Issue: 2
Pages: 354-365
Print publication date: 01/01/2021
Online publication date: 03/09/2020
Acceptance date: 26/07/2020
Date deposited: 19/10/2020
ISSN (print): 0007-1048
ISSN (electronic): 1365-2141
Publisher: Wiley-Blackwell Publishing Ltd
URL: https://doi.org/10.1111/bjh.17043
DOI: 10.1111/bjh.17043
PubMed id: 32880915
Altmetrics provided by Altmetric
